Media releases

People with Parkinson’s are losing an average of two and a half hours a day to debilitating symptoms when their medication wears off, a Parkinson’s UK survey has found.

Leading charities have provided biopharma company Neurolixis joint funding to test a new drug to reduce dyskinesia in people with Parkinson’s

Cancer anti-sickness drug offers hope for hallucinations in Parkinson's

With a second wave imminent, the Government needs to ensure now, more than ever, that everyone is clear about how to keep themselves and others safe.

Our researchers have identified molecules that act as tiny "tweezers" to pull apart proteins that would otherwise form toxic clumps in the brain.

Eating plenty of vegetables and nuts is linked to fewer symptoms that may precede Parkinson’s, according to a new study.

New research funded by Parkinson’s UK has identified further evidence that diabetes may increase risk of Parkinson's.

People with two of the most prevalent neurodegenerative conditions in England are suffering the consequences of having their vital social care slashed during the Covid-19 lockdown.

Parkinson's UK has invested an additional £1 million in NRG Therapeutics Ltd’s mitochondrial drug development programme. This funding boost, on top of an initial £1 million investment, will support the development of a breakthrough drug with the potential to slow or halt the progression of Parkinson’s - something no known treatment can currently do.

Parkinson’s UK has been awarded a £348,600 grant from The National Lottery Community Fund, the largest funder of community activity in the UK, to help deliver vital services and support to people affected by Parkinson’s who are struggling with the impact of COVID-19.